Ritter Pharmaceuticals has announced a public offering of class A units to raise $10m.
The US-based pharmaceutical company plans to use the funds for general corporate purposes, including research and development (R&D) programmes and working capital.
Go deeper with GlobalData
US-based Sienna Biopharmaceuticals plans to raise $74.75m through an initial public offering (IPO) of common stock shares.
Sienna plans to use the funds from the offering towards the development of SNA-120.
Exscientia has formed a strategic partnership with GlaxoSmithKline (GSK) to carry out drug programmes for the latter.
See Also:
The artificial intelligence-based drug discovery company will undertake programmes aimed at discovering novel and selective small molecules for various targets identified by GSK.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAustralian life science company BARD1 Life Sciences has announced two offerings of 137 million common stock shares and 125 million shares priced at A$0.008 ($0.006) a share, to raise a total of A$2m ($1.6m).
BARD1 plans to use the funds towards R&D programmes and for general corporate purposes.
